165 related articles for article (PubMed ID: 38228969)
1. Therapeutic Drug Monitoring of Voriconazole in Critically Ill Pediatric Patients: A Single-Center Retrospective Study.
Taher KW; Almofada R; Alomair S; Albassam AA; Alsultan A
Paediatr Drugs; 2024 Mar; 26(2):197-203. PubMed ID: 38228969
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study.
Wang T; Miao L; Shao H; Wei X; Yan M; Zuo X; Zhang J; Hai X; Fan G; Wang W; Hu L; Zhou J; Zhao Y; Xie Y; Wang J; Guo S; Jin L; Li H; Liu H; Wang Q; Chen J; Li S; Dong Y
Int J Antimicrob Agents; 2022; 60(5-6):106692. PubMed ID: 36372345
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit.
Wang Y; Wang T; Xie J; Yang Q; Zheng X; Dong W; Xing J; Wang X; Dong Y
Pharmacotherapy; 2016 Jul; 36(7):757-65. PubMed ID: 27284960
[TBL] [Abstract][Full Text] [Related]
4. Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients.
Bienvenu AL; Pradat P; Plesa A; Leclerc V; Piriou V; Fellahi JL; Argaud L; Rimmelé T; Menotti J; Aubrun F; Richard JC; Gagnieu MC; Parant F; Chidiac C; Leboucher G; Tod M; Goutelle S
PLoS One; 2021; 16(11):e0260656. PubMed ID: 34818379
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
[TBL] [Abstract][Full Text] [Related]
7. An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.
Zembles TN; Thompson NE; Havens PL; Kaufman BA; Huppler AR
Pharmacotherapy; 2016 Oct; 36(10):1102-1108. PubMed ID: 27548272
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
10. Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: A systematic review and meta-analysis.
Hanai Y; Hamada Y; Kimura T; Matsumoto K; Takahashi Y; Fujii S; Nishizawa K; Takesue Y
J Infect Chemother; 2021 Feb; 27(2):151-160. PubMed ID: 33376032
[TBL] [Abstract][Full Text] [Related]
11. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.
Jin H; Wang T; Falcione BA; Olsen KM; Chen K; Tang H; Hui J; Zhai S
J Antimicrob Chemother; 2016 Jul; 71(7):1772-85. PubMed ID: 26968880
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole monitoring in children with invasive fungal infections.
Tucker L; Higgins T; Egelund EF; Zou B; Vijayan V; Peloquin CA
J Pediatr Pharmacol Ther; 2015; 20(1):17-23. PubMed ID: 25859166
[TBL] [Abstract][Full Text] [Related]
13. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis.
Wang T; Yan M; Tang D; Dong Y; Zhu L; Du Q; Sun D; Xing J; Dong Y
Pharmacotherapy; 2021 Feb; 41(2):172-183. PubMed ID: 33064889
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
[TBL] [Abstract][Full Text] [Related]
15. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
[TBL] [Abstract][Full Text] [Related]
16. Impact of voriconazole plasma concentrations on treatment response in critically ill patients.
Ruiz J; Gordon M; Villarreal E; Peruccioni M; Marqués MR; Poveda-Andrés JL; Castellanos-Ortega Á; Ramirez P
J Clin Pharm Ther; 2019 Aug; 44(4):572-578. PubMed ID: 30851209
[TBL] [Abstract][Full Text] [Related]
17. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
Takesue Y; Hanai Y; Oda K; Hamada Y; Ueda T; Mayumi T; Matsumoto K; Fujii S; Takahashi Y; Miyazaki Y; Kimura T;
Clin Ther; 2022 Dec; 44(12):1604-1623. PubMed ID: 36424314
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated With Voriconazole Concentration in Pediatric Patients.
Kang S; Yee J; Kim JY; Han HW; Kang SO; Lee KE; Gwak HS
Ther Drug Monit; 2020 Dec; 42(6):866-871. PubMed ID: 32868633
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
Hu L; Huang Q; Huang S; Feng Z
Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
[TBL] [Abstract][Full Text] [Related]
20. Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child-Pugh Class C).
Yamada T; Imai S; Koshizuka Y; Tazawa Y; Kagami K; Tomiyama N; Sugawara R; Yamagami A; Shimamura T; Iseki K
Biol Pharm Bull; 2018 Jul; 41(7):1112-1118. PubMed ID: 29760306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
